Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for emergency use in children aged 5-11. Pfizer also announced a clinical study to evaluate the safety and effectiveness of different dosing regimens for the bivalent vaccine in children aged 6 months through 11. 

The FDA recently authorized, and the Centers for Disease Control recommended, a booster dose of the Pfizer bivalent vaccine for Americans aged 12 and older. The bivalent boosters protect against the most recently circulating omicron variants as well as the original virus strain. 
 

Related News Articles

Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…